Medpace Hit With Securities Class Action Over Book-to-Bill and Cancellation Claims

Overview

• The case is filed in the U.S. District Court for the Southern District of Ohio under Durbin v. Medpace Holdings Inc., No. 1:26-cv-00346.
• The suit covers April 22, 2025 through February 9, 2026, and investors have until June 8, 2026 to ask the court to lead the case.
• The complaints say executives understated rising project cancellations and overstated the fourth-quarter 2025 book-to-bill, while calling cancellations “very well behaved.”
• Medpace’s February 9, 2026 update reported a 1.04 book-to-bill versus 1.15 guidance, a gauge of new contract awards versus revenue that signals future growth, which drove about a 15.9% one-day stock drop.
• Plaintiff firm notices report further deterioration into early 2026, including a book-to-bill as low as 0.88 and the president’s planned resignation, claims they say coincided with fresh late‑April share volatility.